ÂÜÀòÂÒÂ×

Dr. Daniel Curran is the Head of the Rare Genetics and Hematology Therapeutic Area Unit (TAU) at Takeda Pharmaceutical Company Ltd. In this role, he leads Takeda’s strategy, research and development efforts to unlock innovation and deliver transformative medicines in the areas of rare genetic and hematologic diseases.

Previously, Dr. Curran served as Head of Takeda’s Center for External Innovation (CEI). In this role, he and his team diversified and transformed Takeda’s research and development pipeline, focusing on partnerships to access cutting-edge technologies and innovation. Over a four-year period, the team completed more than 200 transactions and invested more than $1.5 billion in capital in external relationships and investments.

Prior to his role as Head, CEI, Dr. Curran led the corporate development group at Millennium: The Takeda Oncology Company and was a member of the executive management team. In that role, he oversaw the development and execution of corporate strategic business development initiatives, including licensing arrangements, acquisitions and a range of other transactions.

He has more than 20 years of pharmaceutical experience in strategy, business development, project leadership and development roles.

Prior to Millennium, previous professional experiences include a business development role in the Product Planning and Acquisition group at DuPont Merck Pharmaceuticals.

Dr. Curran received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania and a B.S. in chemistry from King’s College.